Travere CFO sells 642 shares to cover taxes

Travere Therapeutics’ CFO completed a small, non-discretionary share sale to cover tax withholding on vested equity.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) reported that its Chief Financial Officer, Christopher R. Cline, sold 642 shares of common stock on September 2, 2026 at $66.37 per share. According to the company’s disclosure, this sale was a mandatory “sell to cover” transaction to satisfy tax withholding on vested restricted stock units and was not a discretionary trade by the officer, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 642 shares

Net Sell 1 txn

Insider Cline Christopher R.

Role CHIEF FINANCIAL OFFICER

Sold 642 shs ($43K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	642	$66.37	$43K

Holdings After Transaction: Common Stock — 118,016 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Key Figures

Shares sold: 642 shares Sale price per share: $66.37 per share Shares held after transaction: 118,016 shares

3 metrics

Shares sold 642 shares Common stock sold by CFO on September 2, 2026

Sale price per share $66.37 per share Price for the 642 shares sold on September 2, 2026

Shares held after transaction 118,016 shares Direct beneficial ownership by CFO following the sale

Key Terms

restricted stock units, tax withholding obligation, sell to cover, equity incentive plans

4 terms

restricted stock units financial

"in connection with the settlement of vested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligation financial

"cover the tax withholding obligation in connection with the settlement"

sell to cover financial

"by completing a "sell to cover" transaction with a brokerage firm"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

equity incentive plans financial

"mandated by the Issuer's election under its equity incentive plans"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

FAQ

What insider transaction did Travere Therapeutics (TVTX) disclose for its CFO?

Travere Therapeutics disclosed that CFO Christopher R. Cline sold 642 shares of common stock on September 2, 2026 at $66.37 per share. The company states this was a mandatory sale to cover tax withholding on vested restricted stock units, not a discretionary trade.

How many Travere Therapeutics (TVTX) shares does the CFO hold after this Form 4 transaction?

After the reported sale, CFO Christopher R. Cline beneficially holds 118,016 shares of Travere Therapeutics common stock in direct ownership, according to the Form 4 disclosure.

Was the Travere Therapeutics (TVTX) CFO’s share sale a discretionary trade or a sell-to-cover?

The filing states the 642-share sale was a sell to cover transaction required to meet the CFO’s tax withholding obligation arising from vested restricted stock units. Travere Therapeutics notes this sale does not represent a discretionary trade by the CFO.

What price did the Travere Therapeutics (TVTX) CFO receive per share in the reported sale?

The CFO’s sale of 642 shares of Travere Therapeutics common stock on September 2, 2026 was executed at a price of $66.37 per share, based on the Form 4 transaction detail.

Was the Travere Therapeutics (TVTX) CFO’s transaction made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates no Rule 10b5-1 plan is reported for this transaction. Instead, the company explains the sale was mandated by its equity incentive plan as a sell to cover for tax withholding on vested restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 04:14 PM Accepted by SEC EDGAR 09/03/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cline Christopher R.

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, STE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		S(1)		642	D	$66.37	118,016	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)